Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00897520
Recruitment Status : Completed
First Posted : May 12, 2009
Last Update Posted : May 19, 2017
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )

Brief Summary:

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer and predict how patients will respond to treatment.

PURPOSE: This research study is looking at biomarkers in patients with high-risk melanoma receiving high-dose interferon therapy.

Condition or disease Intervention/treatment
Melanoma (Skin) Biological: recombinant interferon alfa Genetic: proteomic profiling Other: immunoenzyme technique Other: laboratory biomarker analysis

Detailed Description:


  • To screen serum specimens using a high throughput protein profiling platform that tests for the highest number of known biomarkers (detectable by antibodies) that could be predictors of response to interferon treatment, autoimmunity, and disease outcome in patients with high-risk melanoma undergoing high-dose interferon (IFNa2b) therapy .
  • To compare soluble factors across all patients at each time point (baseline and during therapy).
  • To compare pre-therapy vs post-therapy serum samples from these patients.
  • To assess the kinetics of soluble factors' appearance, persistence, and disappearance during the 12 months of therapy.
  • To assess whether the amount of specific soluble factors in the pre-therapy sample is predictive of response independent of therapy.
  • To correlate statistically significant factors with S100 and autoimmunity in these patients.
  • To confirm the data obtained with the Luminex technology.

OUTLINE: Patients are stratified according to survival (< 2 years vs > 5 years).

Blood samples collected from patients enrolled in E-1694 are analyzed using high throughput protein profiling by ELISA to compare changes in levels of putative biomarkers of interferon alfa-2b, including cytokines and paired receptors, chemokines, cell adhesion molecules, metalloproteinases, angiogenic markers, growth factors, soluble receptors, signal transduction molecules, hormones, and other biomarkers of disease and dysregulated immune processes, at baseline and during therapy.

Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: PILOT-high Throughput-protein Profiling Analysis of Sera Collected From E1694 Patients Undergoing HDI (Arm B)
Actual Study Start Date : January 14, 2008
Actual Primary Completion Date : January 24, 2010
Actual Study Completion Date : January 24, 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Interferon
U.S. FDA Resources

Primary Outcome Measures :
  1. Serum sample screening via high throughput protein profiling in patients undergoing therapy [ Time Frame: 1 month ]
  2. Comparison of soluble factors [ Time Frame: 1 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 120 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Samples submitted for research from patients participating in E1694


  • Diagnosis of high-risk melanoma
  • Receiving interferon alfa-2b therapy in arm II of clinical trial E-1694


  • Not specified


  • See Disease Characteristics

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00897520

Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Study Chair: Monica Panelli, PhD University of Pittsburgh

Responsible Party: ECOG-ACRIN Cancer Research Group Identifier: NCT00897520     History of Changes
Other Study ID Numbers: CDR0000585297
First Posted: May 12, 2009    Key Record Dates
Last Update Posted: May 19, 2017
Last Verified: May 2017

Keywords provided by Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group ):
stage II melanoma
stage III melanoma
stage IV melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs